<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124464">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008773</url>
  </required_header>
  <id_info>
    <org_study_id>1310496490</org_study_id>
    <nct_id>NCT02008773</nct_id>
  </id_info>
  <brief_title>A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia</brief_title>
  <acronym>VISTA</acronym>
  <official_title>A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheppard Pratt Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Behavioral Health, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laureate Institute for Brain Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansas University Medical Center-Witchita</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is too determine the efficacy of adjunctive valacyclovir, in
      comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working
      (composite score of the Spatial Span and Letter Number Span tests) memory in individuals who
      are HSV-1 positive and early in the course of schizophrenia.

      We hypothesize that individuals who are HSV-1 positive, but not those who are HSV-1
      negative, will demonstrate significant valacyclovir efficacy for visual and working memory.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred and seventy-five participants (N=70 HSV-1 seropositive and N=105 HSV-1
      seronegative) will be randomized 1:1 to receive adjunctive valacyclovir or adjunctive
      placebo for a 16 week period. The primary outcome that will be assessed is improvement in
      changes in visual and working memory scores in HSV-1 positive and negative participants over
      the course of the study. We will also measure the overall cognitive functioning and the
      severity of psychiatric symptoms over the course of the study and will evaluate the
      tolerability and safety of valacyclovir treatment in this population. In addition, we will
      explore the relationship between changes in the levels of inflammatory markers (HSV2, CMV,
      EBV, CRP, and Toxoplasmosis) and treatment response over the course of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual memory</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual memory (Brief Visuospatial Memory Test) in individuals who are HSV-1 positive and early in the course of schizophrenia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Working memory</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to  working memory (composite score of the Spatial Span and Letter Number Span tests) in individuals who are HSV-1 positive and early in the course of schizophrenia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve general cognitive performance as measured by the MATRICS composite score in HSV-1 positive and negative participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional performance</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve functional performance and quality of life as measured by the USCD Performance-Based Skills Assessment, Version B (UPSA-B), Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) and Personal and Social Performance Scale (PSP) and to improve global functional assessments as measured Clinical Global Impressions Severity Scale (CGI-S), and Clinical Global Impressions Severity Improvement scale (CGI-I), and cores in HSV-1 positive and negative participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychosis symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of adjunctive valacyclovir, in comparison to placebo, for general and positive symptoms as measures by the PANSS total and Marder subscale factor scores and negative symptoms as measured by the NSA-16 in HSV-1 positive and negative participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of related adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Review the number of related adverse events to evaluate the tolerability and safety of valacyclovir treatment in this population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To explore changes in the levels of inflammatory markers - HSV2, CMV, EBV, CRP, and Toxoplasmosis - and their relationship to treatment outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3000mg daily oral 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 6 capsules daily oral 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir HCI 500 mg tablets</intervention_name>
    <description>Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks</description>
    <arm_group_label>valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules 6/day oral for 16 weeks</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 40 years of age at study entry.

          -  Able to give written informed consent.

          -  DSM IV-TR Diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
             as confirmed by Structured Clinical Interview for DSM-IV-TR (SCID)

          -  Onset of schizophreniform disorder, schizophrenia, or schizoaffective disorder within
             the past five years as defined by first medical records documentation of these
             conditions

          -  Outpatient or inpatient.

          -  Clinical stability as defined by:

               1. CGI-S score of less than or equal to 4 (moderately ill) at randomization AND

               2. Participants must not have experienced an exacerbation of their illness within 4
                  weeks prior to randomization leading to an intensification of psychiatric care
                  in the opinion of the investigator. Examples of intensification of care include,
                  but are not limited to: inpatient hospitalization, day/partial hospitalization,
                  outpatient crisis management, or psychiatric treatment in an emergency room AND

               3. Antipsychotic treatment stability for at least 4 weeks prior to randomization
                  (no change in antipsychotic dosing, addition of any new antipsychotic
                  medication, or discontinuing an antipsychotic medication)

          -  Fluent in English.

          -  Female participants of childbearing potential must test negative for pregnancy at
             screening visit and agree to use a single, effective, medically acceptable method of
             birth control for the duration of the study.

        Exclusion Criteria:

          -  1. Known IQ less than 70 as determined by medical history.

          -  IV drug use within previous three month prior to study entry.

          -  Any serious active medical condition that affects brain or cognitive functioning
             (e.g., epilepsy, serious head injury, brain tumor or other neurological disorder) in
             the investigator's opinion.

          -  Known medical history of Human Immunodeficiency Virus (HIV)

          -  Receipt of valacyclovir or chemically-related medication within 2 weeks prior to
             randomization.

          -  History of hypersensitivity to valacyclovir or acyclovir as determined by self-report
             and medical history.

          -  DSM-IV diagnosis of substance dependence within 3 months of study entry (with the
             exception of nicotine or caffeine dependence).

          -  Participants who have participated in a clinical trial with any pharmacological
             treatment intervention for which they received study-related medication in the 4
             weeks prior to screening AND participants currently receiving treatment (within 1
             dosing interval plus 4 weeks) with an investigational depot formulation of an
             antipsychotic medication.

          -  Females who are pregnant or planning to become pregnant or breastfeeding or planning
             to do so during the study period.

          -  Participants with current acute, serious, or unstable medical conditions, including,
             but not limited to: inadequately controlled diabetes, asthma, COPD, recent
             cerebrovascular accidents, acute systemic infection or immunologic disease, unstable
             cardiovascular disorders, malnutrition, or hepatic or renal disease, renal including
             renal failure, gastroenterologic, respiratory, endocrinologic, neurologic,
             hematologic including thrombotic thrombocytopenia purpura/hemolytic uremic syndrome,
             or infectious diseases

          -  Participants who require concomitant treatment with any other medication other than
             those allowed as specified in Attachment 2, or with any other medication specifically
             excluded in Attachment 2.

          -  Clinically significant electrocardiogram (ECG) abnormality prior to randomization as
             defined by: participants with a corrected QT interval (Bazett's; QTcB) &gt;450 msec
             (male) or &gt;470 msec (female) prior to randomization. Repeat ECGs will be conducted at
             the discretion of the principal investigator or medical designee.

          -  Test positive for (1) Hepatitis C virus antibody, (2) Hepatitis B surface antigen
             (HBsAg) with or without positive Hepatitis B core total antibody.

          -  Participants with moderate to severe renal impairment as defined by creatinine
             clearance (CrCl) &lt; 60 ml/min (measured by the Cockcroft-Gault equation) at screening.

          -  Participants with hepatic impairment as defined by liver transaminases or total
             bilirubin &gt; 3 Ã— upper limit of normal (ULN).

          -  Participants considered a high risk for suicidal acts - active suicidal ideation as
             determined by clinical interview OR any suicide attempt in 90 days prior to
             screening.

          -  Participants who demonstrate overtly aggressive behavior or who are deemed to pose a
             homicidal risk in the investigator's opinion.

          -  Participants currently receiving cognitive remediation therapy at time of study entry

          -  Participants who have had electroconvulsive therapy (ECT) within 12 months of study
             entry or who will have ECT at any time during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Breier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faith Dickerson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shepard Pratt Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Buchanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Litman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Behavioral Health, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheldon Preskorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laureate Institute for Brain Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikki Mehdiyoun, MA</last_name>
    <phone>3178808495</phone>
    <email>rsparc@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Showalter, MA</last_name>
    <phone>3178808495</phone>
    <email>rsparc@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Psychotic Disorders Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Mehdiyoun, MA</last_name>
      <phone>317-941-4287</phone>
      <email>nmehdiyo@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Breier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalie Case, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariano Erpe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Francis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Megan Gaunnac, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Netsanet Gebregziabher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Kovacs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Liffick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Lindgren, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hai Liu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Malloy, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Mehdiyoun, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkat Polavarapu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Radnovich, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Roebel, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Runyan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Visco, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenifer Vohs, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prevention and Recovery Center for Early Psychosis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Mehdiyoun, MA</last_name>
      <phone>317-880-8494</phone>
      <email>nmehdiyo@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Kulig, MA</last_name>
      <phone>317-880-8495</phone>
      <email>tckulig@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Breier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taylor Duncan-Presson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Kulig, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmalee Metzler, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Ott, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Showalter, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Spradley, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MarShayla Thompson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center-Witchita</name>
      <address>
        <city>Witchita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Rudick</last_name>
      <phone>316-293-3806</phone>
      <email>jrudick@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sheldon Preskorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Macaluso, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrienne Harris-Connell, KRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathy Hay, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Rogers, KRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Rudick, KRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Osing</last_name>
      <phone>410-402-6060</phone>
      <email>josing@mprc.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Buchanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Keller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Kearns</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert McMahon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Wehring, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon August, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Denton, LCSW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Duggan, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Arbach, LCSW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Gorelick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dale Warfel, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Blake, LCSW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judy Liu, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Fischer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Brown, AA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leeka Hubzin, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Simon, LPN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lynne Mathews, LCSW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Osing, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centers for Behavioral Health, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brima Cherif</last_name>
      <phone>301-251-4702</phone>
      <email>bcherif@cbhhealth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Litman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khaled A Khalafallah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shobha L Solomon, MS, FNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stacey M Rumerman, PsyD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa S Conrad</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clarissa Vincent</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brima Cherif</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health System</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Stallings, RN</last_name>
      <phone>410-938-4356</phone>
      <email>cstallings@sheppardpratt.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Katsafanas, BA</last_name>
      <email>ekatsafanas@sheppardpratt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Faith Dickerson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cassie Stallings, RNC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Katsafanas, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucy Schweinfurth, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunil Khushalani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshana Goga, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Origoni, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laureate Institute for Brain Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Santiago</last_name>
      <phone>918-502-5159</phone>
      <email>jsantiago@laureateinstitute.org</email>
    </contact>
    <investigator>
      <last_name>Sheldon Preskorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brent Wurfel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Meyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bobby Bartholomew, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Megan Cole, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tim Collins, KRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dara Crittenden, KRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelly Hopper, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Kinyon, LSW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Reed, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Santiago, MEd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stanleyresearch.org/dnn/</url>
    <description>Stanley Medical Research Institute</description>
  </link>
  <link>
    <url>http://psychiatry.medicine.iu.edu/subsites/psychotic-disorders-program/</url>
    <description>IU Psychotic Disorders Program</description>
  </link>
  <link>
    <url>http://www.sheppardpratt.org/default.aspx</url>
    <description>Sheppard Pratt Health Systems</description>
  </link>
  <link>
    <url>http://www.mprc.umaryland.edu/default.asp</url>
    <description>Maryland Psychiatric Research Center</description>
  </link>
  <link>
    <url>http://www.cbhhealth.com/</url>
    <description>Centers for Behavioral Health, LLC</description>
  </link>
  <link>
    <url>http://www.laureateinstitute.org/</url>
    <description>Laureate Institute for Brain Research</description>
  </link>
  <link>
    <url>http://wichita.kumc.edu/psychiatry-and-behavioral-sciences.html</url>
    <description>Kansas University School of Medicine, Psychiatry</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>December 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Nikki Mehdiyoun</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective</keyword>
  <keyword>schizophreniform</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>HSV1</keyword>
  <keyword>cognition</keyword>
  <keyword>early psychosis</keyword>
  <keyword>valacyclovir</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
